PROSPECTS AND OPPORTUNITIES
Self-medication on the rise, but uncertainty around pseudoephedrine dampens expectations for overall category
Prescribed SKUs still dominate France’s analgesics market, though the self-medication trend is progressing fairly rapidly, particularly in the case of acetaminophen. Rising use of OTC products is likely to provide a positive future for analgesics in the forecast period, particularly with the expansion of stronger formats, (such as 1000mg instead of 500mg in acetaminophen, for example).
Retailers and manufacturers look to avoid shortages
Acetaminophen suffers from overstocking by pharmacists and stockpiling by consumers who anticipate shortages, resulting in a vicious circle. And since the pandemic, consumption of paracetamol has soared, leading to supply tensions and subsequent quota measures.
Sanofi to divest itself of consumer health arm
The French pharmaceutical laboratory Sanofi will separate from its consumer health entity, which includes high-volume drugs that may be sold OTC, such as Doliprane, by the fourth quarter of 2024 at the earliest or in 2025. Sanofi will then focus solely on speciality medicine and vaccines.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Overview:
Understand the latest market trends and future growth opportunities for the Analgesics industry in France with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in France, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
The Analgesics in France report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volume and value sizes, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent research methodology, conducted in-country
This report answers:
- What is the market size of Analgesics in France?
- Which are the leading brands in Analgesics in France?
- How are products distributed in Analgesics in France?
- How has the regulatory and operating environment for Analgesics changed in France?
- How are considerations such as stress, self-medication and shifting consumer lifestyles shaping demand for Analgesics
- How significant are wider health concerns and consumer awareness in determining sales?
- Where is future growth expected to be most dynamic?
Analgesics in France - Category analysis
KEY DATA FINDINGS
Analgesics beset by challenges in 2024
Despite the popularity of acetaminophen, ibuprofen’s woes erode overall category potential
Doliprane’s popularity consolidates Sanofi’s leadership position, while consumers fret over dearth of medical professionals
Self-medication on the rise, but uncertainty around pseudoephedrine dampens expectations for overall category
Retailers and manufacturers look to avoid shortages
Sanofi to divest itself of consumer health arm
Consumer Health in France - Industry Overview
Consumer health in 2024: The big picture
2024 key trends
Competitive landscape
Retailing developments
What next for consumer health?
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
DISCLAIMER
DEFINITIONS
The following categories and subcategories are included:
Analgesics
-
-
- Adult Acetaminophen
- Adult Aspirin
- Adult Combination Products - Analgesics
- Adult Diclofenac
- Adult Dipyrone
- Adult Ibuprofen
- Adult Ketoprofen
- Adult Naproxen
- Adult OTC Triptans
-
- Paediatric Acetaminophen
- Paediatric Aspirin
- Paediatric Combination Products - Analgesics
- Paediatric Dipyrone
- Paediatric Ibuprofen
- Paediatric Naproxen
-
- Acetaminophen
- Aspirin
- Combination Products - Analgesics
- Diclofenac
- Dipyrone
- Ibuprofen
- Ketoprofen
- Naproxen
- OTC Triptans
-
- Topical Analgesics/Anaesthetic
Analgesics
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).
See all of our definitionsWhy buy this report?
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
This report originates from Passport, our Analgesics research and analysis database.
NEW REPORT GUARANTEE
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!